Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy
Background Hairy cell leukemia (HCL) is a rare chronic B cell malignancy, characterized by infiltration of bone marrow, blood and spleen by typical “hairy cells” that bear the BRAFV600E mutation. However, in addition to the intrinsic activation of the MAP kinase pathway as a consequence of the BRAFV600E mutation, the potential participation of other signaling pathways to the pathophysiology of the disease remains unclear as the precise origin of the malignant hairy B cells. Materials and methods Using mRNA gene expression profiling based on the Nanostring technology and the analysis of 290 genes with crucial roles in B cell lymphomas, we defined a 17 gene expression signature specific for HCL. Results Separate analysis of samples from classical and variant forms of hairy cell leukemia showed almost similar mRNA expression profiles apart from overexpression in vHCL of the immune checkpoints CD274 and PDCD1LG2 and underexpression of FAS. Our results point to a post-germinal memory B cell origin and in some samples to the activation of the non-canonical NF-κB pathway. Conclusions This study provides a better understanding of the pathogenesis of HCL and describes new and potential targets for treatment approaches and guidance for studies in the molecular mechanisms of HCL..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:148 |
|---|---|
| Enthalten in: |
Journal of cancer research and clinical oncology - 148(2022), 8 vom: 27. Apr., Seite 2013-2022 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maitre, Elsa [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| RVK: |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s00432-022-04010-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079181769 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079181769 | ||
| 003 | DE-627 | ||
| 005 | 20230519062414.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00432-022-04010-4 |2 doi | |
| 035 | |a (DE-627)OLC2079181769 | ||
| 035 | |a (DE-He213)s00432-022-04010-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a XA 52301 |q VZ |2 rvk | ||
| 100 | 1 | |a Maitre, Elsa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background Hairy cell leukemia (HCL) is a rare chronic B cell malignancy, characterized by infiltration of bone marrow, blood and spleen by typical “hairy cells” that bear the BRAFV600E mutation. However, in addition to the intrinsic activation of the MAP kinase pathway as a consequence of the BRAFV600E mutation, the potential participation of other signaling pathways to the pathophysiology of the disease remains unclear as the precise origin of the malignant hairy B cells. Materials and methods Using mRNA gene expression profiling based on the Nanostring technology and the analysis of 290 genes with crucial roles in B cell lymphomas, we defined a 17 gene expression signature specific for HCL. Results Separate analysis of samples from classical and variant forms of hairy cell leukemia showed almost similar mRNA expression profiles apart from overexpression in vHCL of the immune checkpoints CD274 and PDCD1LG2 and underexpression of FAS. Our results point to a post-germinal memory B cell origin and in some samples to the activation of the non-canonical NF-κB pathway. Conclusions This study provides a better understanding of the pathogenesis of HCL and describes new and potential targets for treatment approaches and guidance for studies in the molecular mechanisms of HCL. | ||
| 650 | 4 | |a Hairy cell leukemia | |
| 650 | 4 | |a NF-KB pathway | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a RGS13 | |
| 650 | 4 | |a EBI3 | |
| 700 | 1 | |a Cornet, Edouard |4 aut | |
| 700 | 1 | |a Debliquis, Agathe |4 aut | |
| 700 | 1 | |a Drenou, Bernard |4 aut | |
| 700 | 1 | |a Gravey, François |4 aut | |
| 700 | 1 | |a Chollet, Didier |4 aut | |
| 700 | 1 | |a Cheze, Stephane |4 aut | |
| 700 | 1 | |a Docquier, Mylène |4 aut | |
| 700 | 1 | |a Troussard, Xavier |4 aut | |
| 700 | 1 | |a Matthes, Thomas |0 (orcid)0000-0002-4875-2477 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d Springer Berlin Heidelberg, 1979 |g 148(2022), 8 vom: 27. Apr., Seite 2013-2022 |w (DE-627)129330493 |w (DE-600)134792-5 |w (DE-576)014586762 |x 0171-5216 |7 nnns |
| 773 | 1 | 8 | |g volume:148 |g year:2022 |g number:8 |g day:27 |g month:04 |g pages:2013-2022 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00432-022-04010-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_287 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 936 | r | v | |a XA 52301 |
| 951 | |a AR | ||
| 952 | |d 148 |j 2022 |e 8 |b 27 |c 04 |h 2013-2022 | ||